A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
Teng LuoShou-Guo ZhangLing-Fei ZhuFei-Xiang ZhangWei LiKe ZhaoXiao-Xue WenMiao YuYi-Qun ZhanHui ChenChang-Hui GeHui-Ying GaoLin WangXiao-Ming YangChang-Yan LiPublished in: Journal of experimental & clinical cancer research : CR (2019)
These findings indicate that Indo5 is associated with marked suppression of c-Met and Trks co-expressing HCC, supporting its clinical development as an antitumor treatment for HCC patients with co-active c-Met and Trks signaling.
Keyphrases